Hsp90 inhibitor: Interim Phase Ib/II data
Interim data from 22 evaluable HER2-positive, advanced breast cancer patients who failed 1-2 prior anti- HER2 regimens in the Phase II portion of an open-label, international Phase Ib/II trial showed that once-weekly 70 mg/m 2 IV AUY922 plus Herceptin trastuzumab produced 5 partial responses. Data from 11 patients in the Phase Ib portion of the trial showed that 55 or 70 mg/m 2 IV AUY922 plus Herceptin led to 1 dose-limiting toxicity (DLT) of grade 3 diarrhea. The recommended dose was once-weekly 70 mg/m 2 IV AUY922 in combination with Herceptin. The most common treatment-related adverse events reported were diarrhea, visual impairment and blurriness, photopsia and nausea. Grade 3/4 adverse events included diarrhea and visual impairment. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...